Home / RAGE/AGER / Human RAGE DuoSet ELISA

Human RAGE DuoSet ELISA

Catalog #: DY1145
26 Citations 5 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
DY1145
Ancillary Products Available
DY008B: DuoSet ELISA Ancillary Reagent Kit 2
DY999B: Substrate Reagent Pack
DY999: Substrate Reagent Pack
Human RAGE ELISA Standard Curve
1 Image
Product Details
Procedure
Citations (26)
FAQs
Supplemental Products
Reviews (5)
Summary Product Features Kit Content Other Reagents Required Data Examples Product Datasheets Preparation and Storage Background

Human RAGE DuoSet ELISA Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Sample Volume Required
100 µL
Assay Range
62.5 - 4,000 pg/mL
Sufficient Materials
For fifteen 96-well plates*
Specificity
Please see the product datasheet

* Provided that the recommended microplates, buffers, diluents, substrates and solutions are used, and the assay is run as summarized in the Assay Procedure provided.

This DuoSet ELISA Development kit contains the basic components required for the development of sandwich ELISAs to measure natural and recombinant human RAGE. The suggested diluent is suitable for the analysis of most cell culture supernate samples. Diluents for complex matrices, such as serum and plasma, should be evaluated prior to use in this DuoSet ELISA.

Product Features

  • Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time
  • Development protocols are provided to guide further assay optimization
  • Assay can be customized to your specific needs
  • Economical alternative to complete kits

Kit Content

  • Capture Antibody
  • Detection Antibody
  • Recombinant Standard
  • Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)

Other Reagents Required


PBS: (Catalog # DY006), or 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2 - 7.4, 0.2 µm filtered

Wash Buffer: (Catalog # WA126), or equivalent

Reagent Diluent: 1% BSA in PBS, pH 7.2-7.4, 0.2 m filtered (R&D Systems Catalog # DY995). Quality of BSA is critical (see Technical Hints).

Blocking Buffer: 1% BSA in PBS, pH 7.2-7.4, 0.2 m filtered (R&D Systems Catalog # DY995). Quality of BSA is critical (see Technical Hints).

Substrate Solution: 1:1 mixture of Color Reagent A (H2O2) and Color Reagent B (Tetramethylbenzidine) (Catalog # DY999)

Stop Solution: 2 N H2SO4 (Catalog # DY994)

Microplates: R&D Systems (Catalog # DY990), or equivalent

Plate Sealers: ELISA Plate Sealers (Catalog # DY992), or equivalent

 

Scientific Data

N/A Human RAGE ELISA Standard Curve View Larger

Human RAGE ELISA Standard Curve

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: RAGE/AGER

RAGE (Receptor for Advanced Glycation End product) is a transmembrane glycoprotein that binds advanced glycation end products (AGEs), beta-amyloid peptides, HMGB1/Amphoterin, and several S100 family proteins. AGEs are adducts formed by the non-enzymatic glycation and oxidation of proteins and lipids. A soluble form can also be generated by MMP-mediated shedding. RAGE is expressed in the CNS during development as well as in adult endothelial cells, smooth muscle cells, pericytes, monocytes, and neurons. It is locally upregulated in vascular inflammation (e.g. diabetes, atherosclerosis, vascular injury, Alzheimer’s disease). At these sites, RAGE binding to S100A1, EN-RAGE/S100A12, or S100B induces inflammatory immune cell adhesion and infiltration as well as vascular smooth muscle proliferation, neointimal expansion, atherosclerotic plaque development, and transport of A-beta into the cerebrospinal fluid. In cancer, RAGE binding to HMGB1, S100A8, or S100A9 promotes tumor growth and metastasis in addition to inflammatory cell infiltration.

To view our complete solutions for RAGE research, visit bio-techne.com.

Long Name:
Receptor for Advanced Glycation End Products
Entrez Gene IDs:
177 (Human); 11596 (Mouse); 81722 (Rat); 403168 (Canine)
Alternate Names:
advanced glycosylation end product-specific receptor; AGER; RAGE isoform delta; RAGE isoform sRAGE-delta; RAGE; Receptor for advanced glycosylation end products; receptor for advanced glycosylation end-products; SCARJ1

Assay Procedure

GENERAL ELISA PROTOCOL

Plate Preparation

  1. Dilute the Capture Antibody (to the working concentration stated in the product datasheet ) in PBS without carrier protein. Immediately coat a 96-well microplate with 100 µL per well of the diluted Capture Antibody. Seal the plate and incubate overnight at room temperature.
  2. Aspirate each well and wash with Wash Buffer, repeating the process two times for a total of three washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential for good performance. After the last wash, remove any remaining Wash Buffer by aspirating or by inverting the plate and blotting it against clean paper towels.
  3. Block each well of the microplate as recommended in the product datasheet. Incubate at room temperature for a minimum of 1 hour.

    Note: The recommended Reagent Diluent typically contains 1% BSA. Some DuoSet Development Kits require alternative blocking agents, or for plates to be blocked overnight with a higher percentage of BSA, please see the product datasheet for details.
     
  4. Repeat the aspiration/wash as in step 2. The plates are now ready for sample addition.

 

PRECAUTION
The Stop Solution suggested for use with this kit is an acid solution. Wear eye, hand, face and clothing protection when using this material.

Assay Procedure

  1. Add 100 µL of sample or standards in Reagent Diluent, or an appropriate diluent, per well. Cover with an adhesive strip and incubate 2 hours at room temperature.
  2. Repeat the aspiration/wash as in step 2 of Plate Preparation.
  3. Add 100 µL of the Detection Antibody, diluted in Reagent Diluent (as recommended in the product datasheet), to each well. Cover with a new adhesive strip and incubate 2 hours at room temperature.
  4. Repeat the aspiration/wash as in step 2 of Plate Preparation.
  5. Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the plate and incubate for 20 minutes at room temperature. Avoid placing the plate in direct light.
  6. Repeat the aspiration/wash as in step 2.
  7. Add 100 µL of Substrate Solution to each well. Incubate for 20 minutes at room temperature. Avoid placing the plate in direct light.
  8. Add 50 µL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing.
  9. Determine the optical density of each well immediately, using a microplate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

Citations for Human RAGE DuoSet ELISA

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

26 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Assessment of EN-RAGE, sRAGE, and its isoforms: cRAGE, esRAGE in obese patients treated by moderate caloric restriction combined with physical activity conducted in hospital condition
    Authors: Kanikowska, D;Kanikowska, A;Strojny, Z;Kawka, E;Zawada, A;Rutkowski, R;Litwinowicz, M;Sato, M;Grzymis?awski, M;Br?borowicz, A;Witowski, J;Korybalska, K;
    Cytokine
    Species: Human
    Sample Types: Serum
  2. Differential Expression of Circulating Damage-Associated Molecular Patterns in Patients with Coronary Artery Ectasia
    Authors: Tsoporis, JN;Triantafyllis, AS;Kalogeropoulos, AS;Izhar, S;Rigopoulos, AG;Rallidis, LS;Sakadakis, E;Toumpoulis, IK;Salpeas, V;Leong-Poi, H;Parker, TG;Rizos, I;
    Biomolecules
    Species: Human
    Sample Types: Plasma
  3. Expression and clinical association of MFG-E8 and TAM receptors in diabetic patients with different stages of microvascular complication: An experimental study
    Authors: Xiong, Y;Wang, B;Jiao, J;Tang, M;Li, K;Jiang, R;Huang, W;
    Medicine
    Species: Human
    Sample Types: Serum
  4. Alveolar macrophages from EVALI patients and e-cigarette users: a story of shifting phenotype
    Authors: Warren, KJ;Beck, EM;Callahan, SJ;Helms, MN;Middleton, E;Maddock, S;Carr, JR;Harris, D;Blagev, DP;Lanspa, MJ;Brown, SM;Paine, R;
    Respiratory research
    Species: Human
    Sample Types: BALF
  5. Time-varying parameters of glycemic control and glycation in relation to arterial stiffness in patients with type 1 diabetes
    Authors: S Helleputte, P Calders, A Rodenbach, J Marlier, C Verroken, T De Backer, B Lapauw
    Cardiovascular Diabetology, 2022-12-09;21(1):277.
    Species: Human
    Sample Types: Serum
  6. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study
    Authors: J Sabbatinel, S Castiglion, F Macrì, A Giuliani, D Ramini, MC Vinci, E Tortato, AR Bonfigli, F Olivieri, A Raucci
    Cardiovascular Diabetology, 2022-06-06;21(1):95.
    Species: Human
    Sample Types: Plasma
  7. Prediction of emergency cerclage outcomes in women with cervical insufficiency: The role of inflammatory, angiogenic, and extracellular matrix-related proteins in amniotic fluid
    Authors: KN Lee, KH Park, YM Kim, I Cho, TE Kim
    PLoS ONE, 2022-05-10;17(5):e0268291.
    Species: Human
    Sample Types: Amniotic Fluid
  8. Clinical and biological markers for predicting ARDS and outcome in septic patients
    Authors: J Villar, R Herrán-Mon, E González-H, M Prieto-Gon, A Ambrós, A Rodríguez-, A Muriel-Bom, R Solano, C Cuenca-Rub, A Vidal, C Flores, JM González-M, MI García-Lao, Genetics o
    Scientific Reports, 2021-11-22;11(1):22702.
    Species: Human
    Sample Types: Serum
  9. Soluble Receptor for Advanced Glycation End-products regulates age-associated Cardiac Fibrosis
    Authors: F Scavello, F Zeni, G Milano, F Macrì, S Castiglion, E Zuccolo, A Scopece, G Pezone, CC Tedesco, P Nigro, G Degani, E Gambini, F Veglia, L Popolo, G Pompilio, GI Colombo, ME Bianchi, A Raucci
    International journal of biological sciences, 2021-06-11;17(10):2399-2416.
    Species: Human
    Sample Types: Cell Culture Supernates
  10. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD
    Authors: KA Pratte, JL Curtis, K Kechris, D Couper, MH Cho, EK Silverman, DL DeMeo, FC Sciurba, Y Zhang, VE Ortega, WK O'Neal, LA Gillenwate, DA Lynch, EA Hoffman, JD Newell, AP Comellas, PJ Castaldi, BE Miller, SD Pouwels, NHTT Hacken, R Bischoff, F Klont, PG Woodruff, R Paine, RG Barr, J Hoidal, CM Doerschuk, JP Charbonnie, R Sung, N Locantore, JG Yonchuk, S Jacobson, R Tal-Singer, D Merrill, RP Bowler
    Respiratory Research, 2021-04-27;22(1):127.
    Species: Human
    Sample Types: Plasma
  11. Advanced Glycation End Products (AGE) and Soluble Forms of AGE Receptor: Emerging Role as Mortality Risk Factors in CKD
    Authors: E Dozio, S Vettoretti, L Caldiroli, S Nerini-Mol, L Tacchini, F Ambrogi, P Messa, MM Corsi Roma
    Biomedicines, 2020-12-21;8(12):.
    Species: Human
    Sample Types: Urine
  12. Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers
    Authors: E Dozio, C Sitzia, L Pistelli, R Cardani, R Rigolini, M Ranucci, MM Corsi Roma
    J Clin Med, 2020-11-23;9(11):.
    Species: Human
    Sample Types: Serum
  13. Circulating Ligands of the Receptor for Advanced Glycation End Products and the Soluble Form of the Receptor Modulate Cardiovascular Cell Apoptosis in Diabetes
    Authors: JN Tsoporis, E Hatziagela, S Gupta, S Izhar, V Salpeas, A Tsiavou, AG Rigopoulos, AS Triantafyl, JC Marshall, TG Parker, IK Rizos
    Molecules, 2020-11-10;25(22):.
    Species: Human
    Sample Types: Plasma
  14. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study
    Authors: EO Melin, J Dereke, M Hillman
    Lipids Health Dis, 2020-10-14;19(1):223.
    Species: Human
    Sample Types: Plasma
  15. Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
    Authors: AK Fotheringh, JI Bagger, DJ Borg, DA McCarthy, JJ Holst, T Vilsbøll, FK Knop, JM Forbes
    Nutrients, 2020-09-24;12(10):.
    Species: Human
    Sample Types: Serum
  16. Longitudinal evaluation of Wnt inhibitors and comparison with others serum osteoimmunological biomarkers in osteolytic bone metastasis
    Authors: E Galliera, L Massaccesi, E de Benedet, E Longhi, D de Toma, MM Corsi Roma, G Banfi
    J. Leukoc. Biol., 2020-02-07;0(0):.
    Species: Human
    Sample Types: Serum
  17. Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health
    Authors: E Dozio, E Vianello, C Sitzia, F Ambrogi, S Benedini, S Gorini, B Rampoldi, R Rigolini, L Tacchini, MMC Romanelli
    J Clin Med, 2020-02-06;9(2):.
    Species: Human
    Sample Types: Plasma
  18. Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging
    Authors: F Scavello, F Zeni, CC Tedesco, E Mensà, F Veglia, AD Procopio, AR Bonfigli, F Olivieri, A Raucci
    Aging (Albany NY), 2019-03-23;11(6):1648-1663.
    Species: Human, Rat
    Sample Types: Cell Culture Supernates, Serum
  19. Regulation of RAGE ectodomain shedding and its role in cell function
    Authors: A Braley, T Kwak, J Jules, E Harja, R Landgraf, BI Hudson
    J Biol Chem, 2016-03-28;0(0):.
    Species: Human
    Sample Types: Cell Culture Supernates
  20. Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.
    Authors: Moser B, Janik S, Schiefer A, Mullauer L, Bekos C, Scharrer A, Mildner M, Renyi-Vamos F, Klepetko W, Ankersmit H
    PLoS ONE, 2014-04-04;9(4):e94118.
    Species: Human
    Sample Types: Serum
  21. Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes.
    Authors: Palombo C, Kozakova M, Morizzo C, Gnesi L, Barsotti M, Spontoni P, Massart F, Salvi P, Balbarini A, Saggese G, Di Stefano R, Federico G
    Cardiovasc Diabetol, 2011-10-08;10(0):88.
    Species: Human
    Sample Types: Plasma
  22. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis.
    Authors: Basta G, Corciu AI, Vianello A, Del Turco S, Foffa I, Navarra T, Chiappino D, Berti S, Mazzone A
    Atherosclerosis, 2010-01-04;210(2):614-8.
    Species: Human
    Sample Types: Plasma
  23. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.
    Authors: Basta G, Castagnini M, Del Turco S, Epistolato MC, Righini P, Sangiorgi GM, De Caterina R, Tanganelli P
    Eur. J. Clin. Invest., 2009-10-07;39(12):1065-72.
    Species: Human
    Sample Types: Plasma
  24. Suspension microarrays for the identification of the response patterns in hyperinflammatory diseases.
    Authors: Hsu HY, Wittemann S, Schneider EM, Weiss M, Joos TO
    Med Eng Phys, 2008-03-03;30(8):976-83.
    Species: Human
    Sample Types: Plasma
  25. Lung epithelial injury markers are not influenced by use of lower tidal volumes during elective surgery in patients without preexisting lung injury.
    Authors: Determann RM, Wolthuis EK, Choi G, Bresser P, Bernard A, Lutter R, Schultz MJ
    Am. J. Physiol. Lung Cell Mol. Physiol., 2007-12-14;294(2):L344-50.
    Species: Human
    Sample Types: BALF
  26. Distribution of the receptor for advanced glycation end products in the human male reproductive tract: prevalence in men with diabetes mellitus.
    Authors: Mallidis C, Agbaje I, Rogers D, Glenn J, McCullough S, Atkinson AB, Steger K, Stitt A, McClure N
    Hum. Reprod., 2007-06-21;22(8):2169-77.
    Species: Human
    Sample Types: Seminal Plasma

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
Loading...

Reviews for Human RAGE DuoSet ELISA

Average Rating: 4.6 (Based on 5 Reviews)

5 Star
60%
4 Star
40%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human RAGE DuoSet ELISA?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human RAGE DuoSet ELISA
By Anonymous on 10/11/2018
Sample Tested: Serum and Plasma
Human RAGE DuoSet ELISA
By Anonymous on 10/08/2018
Sample Tested: EDTA Plasma
Human RAGE DuoSet ELISA DY1145
Human RAGE DuoSet ELISA
By Balaji Mahender on 12/20/2017
Sample Tested: EDTA Plasma
Human RAGE DuoSet ELISA
By Jonatan Dereke on 07/11/2017
Sample Tested: EDTA Plasma

We run human EDTA-plasma samples with this kit at an 1:5 dilution. The observed inter coefficient of variation was a bit higher than preferred.

Human RAGE DuoSet ELISA DY1145
Human RAGE DuoSet ELISA
By Anonymous on 05/22/2017
Sample Tested: Lung tissue